These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 15082118

  • 21. [Rapid detoxification under anesthesia: is it worth while to wait for research-based evidence?].
    Seppä K, Kaukinen S, Mehtonen OP, Poutanen P.
    Duodecim; 1998; 114(20):2090-1. PubMed ID: 11717732
    [No Abstract] [Full Text] [Related]

  • 22. Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
    Hermann D, Klages E, Welzel H, Mann K, Croissant B.
    Addict Biol; 2005 Jun; 10(2):165-9. PubMed ID: 16191669
    [Abstract] [Full Text] [Related]

  • 23. Adolescent opioid abuse.
    O'Brien CP.
    Arch Gen Psychiatry; 2005 Oct; 62(10):1165. PubMed ID: 16203962
    [No Abstract] [Full Text] [Related]

  • 24. Psychometric evaluation of the Dutch version of the Subjective Opiate Withdrawal Scale (SOWS).
    Dijkstra BA, Krabbe PF, Riezebos TG, van der Staak CP, De Jong CA.
    Eur Addict Res; 2007 Oct; 13(2):81-8. PubMed ID: 17356279
    [Abstract] [Full Text] [Related]

  • 25. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.
    Kastelic A, Dubajic G, Strbad E.
    Addiction; 2008 Nov; 103(11):1837-46. PubMed ID: 19032534
    [Abstract] [Full Text] [Related]

  • 26. Unintentional rapid opioid detoxification: case report.
    Singh SM, Sharma B.
    Psychiatr Danub; 2009 Mar; 21(1):65-7. PubMed ID: 19270623
    [Abstract] [Full Text] [Related]

  • 27. The place of detoxification in treatment of opioid dependence.
    Gowing LR, Ali RL.
    Curr Opin Psychiatry; 2006 May; 19(3):266-70. PubMed ID: 16612211
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK, Bhateja P, Singh TG, Singh N.
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [Abstract] [Full Text] [Related]

  • 30. Substance abuse and withdrawal in the critical care setting.
    Tetrault JM, O'Connor PG.
    Crit Care Clin; 2008 Oct; 24(4):767-88, viii. PubMed ID: 18929942
    [Abstract] [Full Text] [Related]

  • 31. Methadone-nicotine interactions in methadone maintenance treatment patients.
    Elkader AK, Brands B, Selby P, Sproule BA.
    J Clin Psychopharmacol; 2009 Jun; 29(3):231-8. PubMed ID: 19440076
    [Abstract] [Full Text] [Related]

  • 32. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial.
    De Jong CA, Laheij RJ, Krabbe PF.
    Addiction; 2005 Feb; 100(2):206-15. PubMed ID: 15679750
    [Abstract] [Full Text] [Related]

  • 33. Effects of opioid prescription medication dependence and detoxification on pain perceptions and self-reports.
    Miller NS, Swiney T, Barkin RL.
    Am J Ther; 2006 Feb; 13(5):436-44. PubMed ID: 16988540
    [Abstract] [Full Text] [Related]

  • 34. Ultra-rapid opioid detoxification: current status and controversies.
    Singh J, Basu D.
    J Postgrad Med; 2004 Feb; 50(3):227-32. PubMed ID: 15377814
    [Abstract] [Full Text] [Related]

  • 35. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.
    Herman I, Shamir D, Bar-Hamburger R, Pick CG, Schreiber S.
    Addict Behav; 2005 Jul; 30(6):1154-67. PubMed ID: 15925125
    [Abstract] [Full Text] [Related]

  • 36. Auricular acupuncture as an adjunct to opiate detoxification treatment: effects on withdrawal symptoms.
    Bearn J, Swami A, Stewart D, Atnas C, Giotto L, Gossop M.
    J Subst Abuse Treat; 2009 Apr; 36(3):345-9. PubMed ID: 19004596
    [Abstract] [Full Text] [Related]

  • 37. Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium.
    Namazi MR.
    Int Immunopharmacol; 2004 Jun; 4(6):709-12. PubMed ID: 15135312
    [No Abstract] [Full Text] [Related]

  • 38. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients.
    Honey BL, Benefield RJ, Miller JL, Johnson PN.
    Ann Pharmacother; 2009 Sep; 43(9):1506-11. PubMed ID: 19690220
    [Abstract] [Full Text] [Related]

  • 39. Should opioid abusers be discharged from opioid-analgesic therapy?
    Compton P.
    Pain Med; 2008 Sep; 9(4):383-90. PubMed ID: 18489627
    [No Abstract] [Full Text] [Related]

  • 40. Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm.
    Farag E, Chahlavi A, Argalious M, Ebrahim Z, Hill R, Bourdakos D, Woo H.
    Anesth Analg; 2006 Dec; 103(6):1618-20. PubMed ID: 17122286
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.